T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria: * Age 18 years or older at the time of informed consent * Histologically confirmed R/R B-cell non-Hodgkin's lymphoma (NHL) * Adequate organ function * Relapsed or refractory (R/R) disease defined as ONE OR MORE of the following: * R/R after ≥ 2 lines of systemic therapy * For the following NHL types: Burkitt lymphoma, Precursor B-cell lymphoblastic lymphoma, or Mantle cell lymphoma: R/R after ≥ 1 lines of systemic therapy * Disease progression or recurrence ≤ 12 months after autologous hematopoietic stem cell transplantation (HSCT) * For subjects who are considered transplant-ineligible: progressive disease as best response after ≥ 4 cycles of first-line therapy and stable disease as best response after ≥ 2 cycles of second-line (salvage) therapy; subject must have received an anti-CD20 monoclonal antibody and an anthracycline as one of their qualifying regimens * All subjects must have received an appropriate chemoimmunotherapy regimen which at a minimum includes an: * Anti-CD20 monoclonal antibody AND * An anthracycline-containing chemotherapy regimen * Positron emission tomography (PET)-positive disease according to Cheson 2014 * Eastern Cooperative Oncology Group (ECOG) ≤ 2 * Toxicities due to prior therapy must be stable and recovered to Grade 1 or less Exclusion Criteria: * Prior CD19-targeted cellular therapy * History of Richter's transformation of chronic lymphocytic leukemia (CLL) * History of another primary malignancy that h…